Targeted Antibodies Replace Chemotherapy in Bone Marrow Stem Cell Clearance

Boston Children’s Hospital is utilizing antibodies to clear stem cells from bone marrow as a replacement for chemotherapy during transplants. This approach aims to reduce the toxicity associated with traditional conditioning regimens for patients treating blood disorders and genetic diseases, according to the institution.

Standard stem cell transplants typically require high-dose chemotherapy or radiation to destroy a patient’s existing bone marrow. This process, known as conditioning, creates space for new, healthy stem cells but often causes severe side effects, including organ damage and a high risk of infection, as reported by Boston Children’s Hospital.

The alternative method uses targeted antibodies to identify and eliminate specific stem cells without the broad cellular destruction caused by chemotherapy. By removing the existing marrow through a targeted biological mechanism, physicians can prepare the body for the infusion of gene-edited or donor cells while avoiding the systemic toxicity of chemical agents.

This technique is particularly relevant for patients undergoing gene therapy for sickle cell disease. In these cases, a patient’s own stem cells are harvested, edited in a laboratory to correct the genetic mutation, and then returned to the body. The use of antibodies to clear the marrow allows these edited cells to engraft more safely.

According to Boston Children’s Hospital, the transition from chemotherapy to antibody-based clearing reduces the physical toll on the patient. This shift potentially expands the number of candidates eligible for cell therapy, including those who may be too frail or have too many comorbidities to withstand traditional chemotherapy.

The process involves the following steps in the clinical application of the new method:

• Administration of antibodies that target specific markers on the surface of the patient’s hematopoietic stem cells.
• Clearance of the existing bone marrow cells to create an available niche for new cells.
• Infusion of the corrected or donor stem cells into the bloodstream.
• Monitoring for the engraftment of the new cells in the bone marrow.

Medical researchers are focusing on this method to mitigate the long-term risks of chemotherapy, such as infertility and secondary malignancies. By utilizing the immune system’s own precision, the hospital intends to make the transplant process less invasive and more accessible for pediatric and adult populations with blood disorders.